Skip to main content

Tagraxofusp in Treating Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm after Stem Cell Transplant

Trial Status: Active

This phase II trial studies the side effects of tagraxofusp in treating patients with blastic plasmacytoid dendritic cell neoplasm after stem cell transplant. Tagraxofusp is a type of immunotoxin that is made by linking a protein called IL-3 to a toxic substance. Tagraxofusp may help find cancer cells that express IL-3 and kill them without harming normal cells.

Inclusion Criteria

  • Eligible patients will be aged >= 18 years. Pediatric patients age 2 years and older will be considered on a case by case basis.
  • Diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN) according to World Health Organization (WHO) classification or confirmed by hematopathology
  • The patients must be in partial response or better
  • > 30 days post-transplant without active or chronic infections
  • Karnofsky performance status >= 60%; Lansky >= 60
  • Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal by multigated acquisition (MUGA) scan or echocardiogram within 30 days of first protocol treatment
  • Diffusion capacity of the lung for carbon monoxide (DLCO) > 40% of predicted value (corrected for hemoglobin) within 3 months of registration
  • Forced expiratory volume in 1 second (FEV1) > 40% of predicted value within 3 months of registration
  • Forced vital capacity (FVC) > 40% of predicted value within 3 months of registration
  • Serum creatinine =< 1.5 mg/dL (133 mmol/L)
  • Serum albumin >= 3.2 g/dL (or >= 32 g/L) without IV albumin within the previous 72 hours
  • Bilirubin =< 1.5 x the upper limit of normal ([ULN] except patients with Gilbert syndrome in whom bilirubin level of > 1.5 x ULN will be allowed)
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times ULN
  • Hemoglobin >= 8 g/dL with or without transfusion in the last 7 days
  • Absolute neutrophil count (ANC) >= 1000 without granulocyte colony stimulating factor (GCSF) or granulocyte-macrophage colony-stimulating factor (GMCSF) in the last 2 weeks prior to screening
  • Platelets >= 50,000micro/mL
  • For allo-HCT, no >= grade 2 visceral (gut or liver) acute graft versus host disease (GVHD) and no >= grade 3 or any other acute GVHD (patients with chronic GVHD will be allowed at the discretion of the investigator)
  • Patient agrees to use acceptable contraceptive methods for the duration of time in the study, and to continue to use acceptable contraceptive methods for 2 months after the last tagraxofusp infusion
  • Woman of child bearing potential (WOCBP) with a negative serum or urine pregnancy test within 14 days of tagraxofusp treatment
  • Patient or patient’s legal representative, parent(s) or guardian able to sign informed consent
  • The patient can adhere to the study visit schedule and other protocol requirements, including follow-up for survival assessment

Exclusion Criteria

  • The patient has persistent clinically significant non-hematologic toxicities >= grade 2 (excluding alopecia, nausea, and fatigue)
  • Evidence of central nervous system (CNS) involvement
  • Uncontrolled and active pulmonary disease
  • Requirement for oxygen treatment
  • Receiving chemotherapy, radiotherapy or other anti-cancer therapy within 14 days of first dose of study drug. There must be at least a 6-week interval from the last immunotherapy therapy
  • Uncontrolled infection
  • Human immunodeficiency virus (HIV)/hepatitis B and/or C
  • Any history of invasive malignancy in the last 2 years excluding any malignancy such as cervical cancer or skin cancer (excluding melanoma) that is considered cured at the time of screening
  • Pregnant or breast-feeding woman
  • Patient has uncontrolled intercurrent illness or medical/psychiatric condition that would limit compliance with study requirements or that would in the investigator’s opinion place the patient at an unacceptably high risk for toxicities
  • Clinical significant cardiopulmonary disease including uncontrolled or New York Heart Association (NYHA) class 3 or 4 congestive heart failure, uncontrolled angina, uncontrolled hypertension, uncontrolled arrhythmia, myocardial infarction or stroke within 6 months of first protocol treatment or corrected QT (QTc) > 480 ms


M D Anderson Cancer Center
Status: ACTIVE
Contact: Qaiser Bashir
Phone: 713-792-8750


I. To evaluate the safety of tagraxofusp-erzs (tagraxofusp) in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) after autologous (auto) or allogeneic (allo) hematopoietic cell transplantation (HCT).


I. To estimate progression-free survival (PFS) in patients with BPDCN receiving maintenance therapy with tagraxofusp after auto-HCT or allo-HCT.

II. To estimate the overall survival (OS) in patients with BPDCN receiving maintenance therapy with tagraxofusp after auto-HCT or allo-HCT.


Within day 45 and 120 after stem cell transplant, patients receive tagraxofusp-erzs intravenously (IV) over 15 minutes on days 1-3 of cycles 1-4 and days 1-2 of subsequent cycles. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for up to 1 year.

Trial Phase Phase II

Trial Type Treatment

Lead Organization
M D Anderson Cancer Center

Principal Investigator
Qaiser Bashir

  • Primary ID 2018-0646
  • Secondary IDs NCI-2019-03832
  • ID NCT04317781